{
  "abstract": "Introduction: Qualitative exit interviews with people who recently completed a clinical trial can provide in-depth insights into their treatment experience and the benefits they consider most meaningful. The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.\n\nMethods: Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial. Interviews were conducted by telephone or web-based conference using a semi-structured interview guide. The interviews were transcribed and analyzed following a content analysis approach.\n\nResults: In total, 147 people were invited to participate in exit interviews across 10 US trial sites. A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide. Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%). Some also noted improvement in conditions other than T2D, including joint pain/osteoarthritis (18.9%) and sleep apnea (8.1%). Nearly all participants said these treatment-related changes were meaningful. Participants described improvements in quality of life and daily activities associated with treatment. The most commonly reported adverse event was nausea (28.4%). Most participants said they would be very likely (77.0%) or likely (16.2%) to recommend their treatment to others.\n\nConclusions: Exit interview results indicate that self-reported treatment benefits were important to people who received long-term treatment with dulaglutide or tirzepatide.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13300-026-01907-y.",
  "abstract_shown": true,
  "affiliations": [
    "PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA USA",
    "Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Katie D. Stewart",
      "orcid": "0009-0003-4204-807X"
    },
    {
      "affs": [
        0
      ],
      "name": "Louis S. Matza",
      "orcid": "0000-0001-6374-5948"
    },
    {
      "affs": [
        1
      ],
      "name": "Chanadda Chinthammit",
      "orcid": "0009-0002-0998-2437"
    },
    {
      "affs": [
        1
      ],
      "name": "Imre Pavo"
    },
    {
      "affs": [
        1
      ],
      "name": "Amy K. Bartee"
    },
    {
      "affs": [
        1
      ],
      "name": "Kristina S. Boye",
      "orcid": "0000-0002-5953-5929"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/01w83mv7y3m1z.bib",
  "cited_by": 0,
  "doi": "10.1007/s13300-026-01907-y",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13728037/",
  "id": "01w83mv7y3m1z",
  "issns": [
    "1869-6953",
    "1869-6961"
  ],
  "landing_url": "https://doi.org/10.1007/s13300-026-01907-y",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2712|Diabetes Treatment and Management"
    ]
  ],
  "openalex": "W7213467058",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s13300-026-01907-y.pdf",
  "pmcid": "PMC13728037",
  "pmid": "42754765",
  "published": "2026-09-17",
  "publisher": "Springer",
  "ris": "https://research.draconitic.com/paper/01w83mv7y3m1z.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T12:23:48Z",
      "native_id": "PMC13728037",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s13300-026-01907-y"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Diabetes Treatment and Management",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial",
  "title_text": "Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:21:06Z",
  "url": "https://research.draconitic.com/paper/01w83mv7y3m1z",
  "venue": "Diabetes Therapy",
  "versions": []
}